The U.S. Food and Drug Administration has approved German pharmaceutical company Boehringer Ingelheim's Pradaxa (dabigatran etexilate) to treat deep venous thrombosis and pulmonary embolism for patients who have been treated with an injectable anticoagulant for five to 10 days, according to a company news release.
Pradaxa has also been approved to reduce the risk of recurrent venous thromboembolism patients who have previously been treated.
In clinical trials, Pradaxa demonstrated a 92 percent reduction of risk of recurrent blood clots compared to a placebo, according to the news release.
More Articles on FDA Approvals:
FDA Clears Intuitive Surgical's Latest da Vinci Robot Upgrade
FDA Approves Alprolix for Hemophilia B Treatment
FDA Approves Otezla for Psoriatic Arthritis Treatment